Loading...
Type 1 narcolepsy (NT1) is associated with excessive daytime sleepiness (EDS), cataplexy (a sudden, brief loss of muscle tone triggered by an emotional event), hypnagogic and hypnopompic hallucinations, and sleep paralysis. A loss of orexin-producing neurons in the hypothalamus leads to NT1. Oveporexton, an oral orexin receptor-2–selective agonist, targets this underlying mechanism. In two multinational, industry-sponsored, phase 3, randomized, placebo-controlled trials, 273 participants aged 18–70 years with NT1 and at least four cataplexy episodes per week received twice daily (1 mg or 2 mg) oveporexton or placebo for 12 weeks. Participants were off other narcolepsy treatments for at least 2 weeks. Numerous conditions were excluded…